Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers

PURPOSE: Romidepsin is a potent histone deacetylase inhibitor (HDI) with activity in T-cell lymphoma. Given preclinical data demonstrating greater induction of gene expression with longer exposures to HDIs, a phase I study of a days 1, 3, and 5 romidepsin schedule was evaluated. A secondary objectiv...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Amiri-Kordestani, Laleh, Luchenko, Victoria, Peer, Cody J., Ghafourian, Kambiz, Reynolds, James, Draper, Deb, Frye, Robin, Woo, Sue, Venzon, David, Wright, John, Skarulis, Monica, Figg, William D., Fojo, Tito, Bates, Susan E., Piekarz, Richard L.
Формат: Artigo
Язык:Inglês
Опубликовано: 2013
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3967244/
https://ncbi.nlm.nih.gov/pubmed/23757352
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-0095
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы